Home › Trials › NCT04251052

Comparing two surgical procedures to lower ovarian cancer risk in women with BRCA1 mutations

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Not applicable Interventional NRG Oncology · NCT04251052

This study is testing if a less invasive surgery can lower the risk of ovarian cancer just as well as a more extensive surgery for women with BRCA1 mutations.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment1956 (estimated)
Ages35 Years to 50 Years
SexFemale
SponsorNRG Oncology Academic / other
Drugs / interventionschemotherapy
Locations549 sites (Birmingham, Alabama and 548 other locations)
Trial IDNCT04251052 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the effectiveness of two surgical procedures, bilateral salpingectomy (BLS) and bilateral salpingo-oophorectomy (BSO), in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. The primary objective is to determine if BLS is non-inferior to BSO in terms of cancer risk reduction. Secondary objectives include assessing the impact of these procedures on quality of life, menopausal symptoms, and decision-making processes. The study involves patients aged 35-50 who are undergoing these surgical interventions and includes various assessments to evaluate outcomes.

Who should consider this trial

Good fit: Ideal candidates are women aged 35-50 with pathogenic BRCA1 mutations who are considering risk-reducing surgery.

Not a fit: Patients who have already undergone a hysterectomy that included bilateral salpingectomy or those without intact ovaries and fallopian tubes may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a less invasive surgical option for women with BRCA1 mutations while effectively reducing their risk of ovarian cancer.

How similar studies have performed: Other studies have explored similar surgical approaches, but this specific comparison of BLS and BSO in BRCA1 mutation carriers is novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Individuals 35-50 years of age, inclusive
* Patients who will undergo risk-reducing salpingo-oophorectomy (RRSO) (for the BSO arm) and patients who have declined or elected to defer BSO after proper counselling to clearly explain the standard of care for BRCA1 mutation carriers and are undergoing salpingectomy (for the BLS arm with delayed oophorectomy arm). Concurrently planned hysterectomy with either arm is permitted
* At least one intact ovary and fallopian tube is in situ at the time of counseling, consent, and registration. Prior hysterectomy is allowed provided it did not include bilateral salpingectomy. Prior tubal ligation is allowed if one ovary and fallopian tube (with fimbria not removed) are present
* Positive Clinical Laboratory Improvement Act (CLIA)-approved test results for pathogenic or likely pathogenic germline BRCA1 mutation in the patient. Documentation of the result is required
* Patients may be premenopausal or menopausal
* Pelvic ultrasound (transvaginal imaging preferred, but transabdominal imaging is acceptable) or pelvic MRI and CA-125 within 180 days of registration
* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
* Individuals who are currently pregnant or plan to become pregnant in the future through assisted reproductive technologies and who have received proper counseling are eligible. Individuals who are currently pregnant and plan bilateral salpingectomy at the time of a planned cesarean section are eligible. Patients must understand that they will not be able to become pregnant naturally in the future

Exclusion Criteria:

* Individuals with a history of any prior cancer who have received cytotoxic chemotherapy within the past 30 days or radiotherapy to abdomen or pelvis at any prior time. Endocrine therapy or maintenance ERBB2/HER2 targeted therapy is allowed. Maintenance immune checkpoint inhibitor therapy is allowed. Maintenance therapy with PARP in inhibitor is allowed.
* Prior history of ovarian cancer, including low malignant potential neoplasms (LMP), primary peritoneal carcinoma, or fallopian tube carcinoma
* Patients medically unfit for the planned surgical procedure
* Patients with abnormal screening tests (pelvic ultrasound, pelvic MRI, CA-125) suspicious for occult or gross pelvic malignancy within the past 180 days

  * An abnormal pelvic ultrasound (or pelvic MRI) is defined as morphologic or structural variations suspicious for ovarian malignancy. Complex cystic lesions felt to represent a benign lesion are not exclusionary. Simple cysts of any size are not exclusionary
  * An abnormal CA-125 is defined as a level \> 50U/ml in premenopausal individuals if they are not current users of oral contraceptives; an abnormal CA-125 is defined as a level \> 40U/ml for premenopausal individuals who are current users of oral contraceptives (Skates 2011). An abnormal CA-125 is defined as a level \> 35 U/ml in postmenopausal individuals

Where this trial is running

Birmingham, Alabama and 548 other locations

+499 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Ovarian Carcinoma
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.